Lu Mingqian, Lu Hongda, Kong Qingzhi
Clinical Medical College, Hubei University of Chinese Medicine, Wuhan 430061, Hubei province, China.
Expert Rev Anticancer Ther. 2015 Apr;15(4):425-32. doi: 10.1586/14737140.2015.1007957. Epub 2015 Feb 3.
Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling. Even though androgen deprivation therapy shows its initial effectiveness on shrinking tumor size, it eventually fails to cure advanced PCa, which is determined by the occurrence of castration-resistance. In this review, we summarize the widely accepted mechanisms that account for castration-resistant PCa and discuss potential therapeutic targets.
前列腺癌(PCa)是男性癌症相关死亡的第二大主要原因。雄激素受体在PCa的发生和发展中起关键作用。目前,雄激素剥夺疗法因其有效抑制雄激素受体信号传导而成为PCa患者的标准治疗方法。尽管雄激素剥夺疗法在缩小肿瘤大小方面显示出初步疗效,但最终无法治愈晚期PCa,这是由去势抵抗的发生所决定的。在本综述中,我们总结了导致去势抵抗性PCa的广泛接受的机制,并讨论了潜在的治疗靶点。